229 related articles for article (PubMed ID: 22210323)
1. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents.
Mu J; Pinkstaff J; Li Z; Skidmore L; Li N; Myler H; Dallas-Yang Q; Putnam AM; Yao J; Bussell S; Wu M; Norman TC; Rodriguez CG; Kimmel B; Metzger JM; Manibusan A; Lee D; Zaller DM; Zhang BB; DiMarchi RD; Berger JP; Axelrod DW
Diabetes; 2012 Feb; 61(2):505-12. PubMed ID: 22210323
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody.
Huang J; Ishino T; Chen G; Rolzin P; Osothprarop TF; Retting K; Li L; Jin P; Matin MJ; Huyghe B; Talukdar S; Bradshaw CW; Palanki M; Violand BN; Woodnutt G; Lappe RW; Ogilvie K; Levin N
J Pharmacol Exp Ther; 2013 Aug; 346(2):270-80. PubMed ID: 23720456
[TBL] [Abstract][Full Text] [Related]
3. Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice.
Camacho RC; Zafian PT; Achanfuo-Yeboah J; Manibusan A; Berger JP
Eur J Pharmacol; 2013 Sep; 715(1-3):41-5. PubMed ID: 23831019
[TBL] [Abstract][Full Text] [Related]
4. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.
Xu J; Stanislaus S; Chinookoswong N; Lau YY; Hager T; Patel J; Ge H; Weiszmann J; Lu SC; Graham M; Busby J; Hecht R; Li YS; Li Y; Lindberg R; Véniant MM
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1105-14. PubMed ID: 19706786
[TBL] [Abstract][Full Text] [Related]
5. A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol.
Huang Z; Wang H; Lu M; Sun C; Wu X; Tan Y; Ye C; Zhu G; Wang X; Cai L; Li X
PLoS One; 2011; 6(6):e20669. PubMed ID: 21673953
[TBL] [Abstract][Full Text] [Related]
6. Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation.
Xu J; Bussiere J; Yie J; Sickmier A; An P; Belouski E; Stanislaus S; Walker KW
Bioconjug Chem; 2013 Jun; 24(6):915-25. PubMed ID: 23594041
[TBL] [Abstract][Full Text] [Related]
7. Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes.
Xu P; Ye X; Zhang Y; Yuan Q; Liu M; Wu Q; Ren G; Li D
J Diabetes Complications; 2015; 29(1):5-12. PubMed ID: 25456819
[TBL] [Abstract][Full Text] [Related]
8. Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice.
Ye X; Qi J; Wu Y; Yu D; Xu P; Li S; Zhu S; Wu Q; Ren G; Li D
Diabetes Metab; 2015 Feb; 41(1):82-90. PubMed ID: 25451186
[TBL] [Abstract][Full Text] [Related]
9. FGF21 Normalizes Plasma Glucose in Mouse Models of Type 1 Diabetes and Insulin Receptor Dysfunction.
Diener JL; Mowbray S; Huang WJ; Yowe D; Xu J; Caplan S; Misra A; Kapur A; Shapiro J; Ke X; Wu X; Bose A; Panza D; Chen M; Beaulieu V; Gao J
Endocrinology; 2021 Sep; 162(9):. PubMed ID: 33951176
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.
Xu J; Lloyd DJ; Hale C; Stanislaus S; Chen M; Sivits G; Vonderfecht S; Hecht R; Li YS; Lindberg RA; Chen JL; Jung DY; Zhang Z; Ko HJ; Kim JK; Véniant MM
Diabetes; 2009 Jan; 58(1):250-9. PubMed ID: 18840786
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus.
So WY; Leung PS
Med Res Rev; 2016 Jul; 36(4):672-704. PubMed ID: 27031294
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
[TBL] [Abstract][Full Text] [Related]
13. A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis.
Pan Q; Lin S; Li Y; Liu L; Li X; Gao X; Yan J; Gu B; Chen X; Li W; Tang X; Chen C; Guo L
EBioMedicine; 2021 Jan; 63():103202. PubMed ID: 33421947
[TBL] [Abstract][Full Text] [Related]
14. A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog.
Song L; Zhu Y; Wang H; Belov AA; Niu J; Shi L; Xie Y; Ye C; Li X; Huang Z
Biomaterials; 2014 Jun; 35(19):5206-15. PubMed ID: 24685265
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice.
Kim HW; Lee JE; Cha JJ; Hyun YY; Kim JE; Lee MH; Song HK; Nam DH; Han JY; Han SY; Han KH; Kang YS; Cha DR
Endocrinology; 2013 Sep; 154(9):3366-76. PubMed ID: 23825123
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats.
Sarruf DA; Thaler JP; Morton GJ; German J; Fischer JD; Ogimoto K; Schwartz MW
Diabetes; 2010 Jul; 59(7):1817-24. PubMed ID: 20357365
[TBL] [Abstract][Full Text] [Related]
17. Long-lasting hypoglycemic effect of modified FGF-21 analog with polyethylene glycol in type 1 diabetic mice and its systematic toxicity.
Ye X; Qi J; Wu Q; Yu D; Li S; Wu Y; Li D
Eur J Pharmacol; 2016 Jun; 781():198-208. PubMed ID: 27089817
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
Ye X; Qi J; Yu D; Wu Y; Zhu S; Li S; Wu Q; Ren G; Li D
J Diabetes Complications; 2017 Apr; 31(4):726-734. PubMed ID: 28143735
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling-dependent manner.
Pan Y; Wang B; Zheng J; Xiong R; Fan Z; Ye Y; Zhang S; Li Q; Gong F; Wu C; Lin Z; Li X; Pan X
J Cell Mol Med; 2019 Feb; 23(2):1059-1071. PubMed ID: 30461198
[TBL] [Abstract][Full Text] [Related]
20. FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis.
Mottillo EP; Desjardins EM; Fritzen AM; Zou VZ; Crane JD; Yabut JM; Kiens B; Erion DM; Lanba A; Granneman JG; Talukdar S; Steinberg GR
Mol Metab; 2017 Jun; 6(6):471-481. PubMed ID: 28580278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
